Acasti Pharma

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

Document Security Systems

GEE Group

Meten Holding Group Ltd.

New Gold

Are these top penny stocks worth watching in July 2021? The post 5 Hot Penny Stocks You Need to Know About in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks You Need to Know About in 2021

NEW YORK, July 3, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Acasti Pharma, Inc. ("ACST" or the "Company") ( ACST ) relating to its proposed merger with Grace Therapeutics, Inc. ACST shareholders are expected to own approximately 55% of the combined company. The investigation focuses on whether Acasti Pharma, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST

Adamis Pharmaceuticals

Ampio Pharmaceuticals Inc

BIOLASE

Jaguar Health

Northwest Biotherapeutics, Inc.

Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?

Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist

Ashford Hospitality Trust

Vinco Ventures

BEST Inc - ADR

Farmmi

Ideanomics Inc

Which penny stocks are on your watchlist today? Here's 7 for some inspiration The post What Penny Stocks to Buy Today?

What Penny Stocks to Buy Today? 7 Small-Caps to Watch Right Now

The stock price of Acasti Pharma Inc (NASDAQ: ACST) increased by over 35% pre-market. This is why it happened.

ACST Stock Price Increases Over 35% Pre-Market: Why It Happened

1847 GOEDEKER INC.

Globalstar

Histogen

Regulus Therapeutics

Sunshine Biopharma

Senseonics Holdings

Looking for the best penny stocks to watch in July? Check these 7 out for your list The post Reddit Penny Stocks to Buy?

Reddit Penny Stocks to Buy? 7 You Need to Know About In July

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) (FRA:A1PA) announced its operating and financial results for the fiscal year ended 31 March, along with an update on its proposed acquisition of Grace Therapeutics.  Acasti, a biopharmaceutical innovator, reported a narrower loss from operating activities of $16.4 million, compared to a loss of $24.4 million a year earlier, due mainly to a reduction in expenses.

Acasti Pharma reduces losses as it progresses Grace Therapeutics transaction

Cinedigm

Electrameccanica

Penny stocks to buy under $5? Check these 3 out for your watchlist The post Best Penny Stocks to Buy Under $5?

Best Penny Stocks to Buy Under $5? 3 For Your Morning Watchlist

Advaxis

Agenus

Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25%

LAVAL, Québec, May 17, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department (the “Staff”) indicating that, based upon the Company's non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a) (the “Rule”) as of May 10, 2021, the Company's securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company has previously disclosed and expected such notification from Nasdaq and believes it has options to regain compliance, preferably in connection with its proposed acquisition of Grace Therapeutics, Inc. (“Grace”) as is often done in connection with similar transactions.

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Chiasma

Ferro

Domtar

NEW YORK, May 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Domtar Corporation (NYSE: UFS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Paper Excellence for $55.50 per share in cash. If you are a Domtar shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Acasti Pharma Inc. (“Acasti” or the “Company”) (NasdaqGS: ACST) with Grace Therapeutics Inc., pursuant to which Acasti shareholders will end up owning only approximately 55% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the mer

ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST

The stock price of Acasti Pharma Inc (NASDAQ: ACST) increased by over 4% pre-market. This is why it happened.

ACST Stock: Over 4% Increase Pre-Market Explanation

Shares of Acasti Pharma, Inc. (NASDAQ:ACST) fell to the 40-cent support level. Then they rallied and hit resistance at the 58 cents level and are selling off again.

Acasti Pharma Falls To Support, Stages Huge Rebound

Acasti Pharma Inc (NASDAQ: ACST) has agreed to acquire privately-held Grace Therapeutics Inc in an all-stock transaction. After the consummation of the deal, Acasti would own approximately 55% of the combined company on a pro forma basis, and Grace would own the remaining 45%.

Acasti Pharma To Acquire Grace Therapeutics: Highlights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Acasti Pharma Inc. (NASDAQ: ACST) and Grace Therapeutics Inc. is fair to Acasti shareholders. Under the merger, Grace stockholders will receive newly issued Acasti common shares. Upon closing, Acasti securityholders are expected to own approximately 55% of the combined company's common shares on a pro forma basis, subject to certain adjustments. Halper Sadeh encourages Acasti s

Acasti Pharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Acasti Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ACST

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has announced a definitive agreement to acquire Grace Therapeutics Inc, a privately-held biopharmaceutical company developing drug delivery technologies for the treatment of rare and orphan diseases.  The deal would have Acasti acquire Grace's entire therapeutic pipeline consisting of three unique clinical stage and multiple preclinical stage assets, supported by an intellectual property portfolio of more than 40 granted and pending patents globally.

Acasti Pharma unveils proposal to buy Grace Therapeutics and its portfolio of drug candidates in all-stock deal

Assertio Therapeutics Inc

T2 Biosystems

Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Investors Need to Watch In 2021

The stock price of Acasti Pharma Inc (NASDAQ: ACST) increased by over 10% pre-market. This is why it happened.

ACST Stock: Over 10% Increase Pre-Market Explanation

Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the FDA

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Luokung Technology Corp

Torchlight Energy Resources

Are penny stocks under $2 worth it? Take a look at these 3 to decide The post Best Penny Stocks to Buy Under $2?

Best Penny Stocks to Buy Under $2? Check These 3 Out

The future course of ACST stock depends largely on the company's lead drug candidate, CaPre. Any good news could send the shares higher.

Wait for Acasti Pharma Stock to Fall Further Before Buying

From time to time, ACST stock tends to have massive price spikes. It's too volatile for a long-term position, but may be a trader's paradise.

Acasti Pharma Stock Is Only Ideal for a Short-Term Trade

LAVAL, Quebec, March 08, 2021 (GLOBE NEWSWIRE) -- As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of its “at-the market” equity offering program.

Acasti Pharma Provides Update on Recent Financing Activities

TRILOGY 2 study on CaPre did not meet its primary endpoint CaPre was a krill-oil derived prescription drug designed to treat hypertriglyceridemia What Acasti Pharma does: Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) had been developing a krill-oil derived prescription drug called CaPre to treat hypertriglyceridemia (high levels of triglycerides in the blood), which is known to contribute to heart disease. However, in August last year, the company revealed that a TRILOGY 2 study on CaPre had not met its primary endpoint and said it would not file a New Drug Application with the US Food and Drug Administration.

Acasti Pharma awaiting business review outcome after CaPre drug trial disappointment

News for Acasti Pharma Stock (ACST)